RAF inhibitors achieve unprecedented but mainly transient clinical responses in melanoma patients whose tumors harbor an activating BRAF mutation. One notable side-effect of RAF inhibitors is the stimulation of cutaneous skin tumors, arising in about 30% of patients receiving these drugs, which are thought to develop as a result of inhibitor-induced activation of wildtype Raf in occult precursor skin lesions. This effect raises the possibility that less manageable tumors might also arise in other epithelial tissues. Here we provide preclinical evidence supporting this disquieting hypothesis by showing that the RAF inhibitors PLX-4032 (vemurafenib) and GDC-0879 precipitate the development of cell-autonomous, Ras-driven tumors in skin and gastric epithelia. The magnitude of the effects correlated with the inhibitors' relative abilities to induce ERK activation. Epidermis-restricted ablation of either B-Raf or C-Raf prevented PLX-4032-induced ERK activation and tumorigenesis. In contrast, GDC-0879 induced ERK activation and tumorigenesis in B-Raf-deficient epidermis, whereas C-Raf ablation blocked GDC-0879-induced tumorigenesis (despite strong ERK activation) by preventing Rok-ɲ-mediated keratinocyte de-differentiation. Thus, inhibitor-induced ERK activation did not require a specific Raf kinase. ERK activation was necessary, but not sufficient for Ras + Raf inhibitor-induced tumorigenesis, while C-Raf down-regulation of Rok-ɲ was essential even in the face of sustained ERK signaling to prevent differentiation and promote tumorigenesis. Taken together, our findings suggest that combination therapies targeting ERK-dependent and ERK-independent functions of Raf may be more efficient but also safer for cancer treatment.
INTRODUCTION
RAF inhibitors have revolutionized the treatment of metastatic melanoma patients whose cancers harbor the BRAF mutation V600E, which increases kinase activity and leads to the constitutive activation of the MEK/ERK pathway (1) (2) (3) . The side effects of the drugs are mild but include the development, in up to 30% of the patients, of keratoacanthomas or cutaneous squamous cell carcinomas (cSCC). In cultured cells, Raf inhibitors can paradoxically stimulate Raf kinase activity and MEK/ERK activation, particularly in the presence of activated Ras. The precise mechanism of action of the Raf inhibitors is yet unclear; activation/dimerization induced by the direct binding of the drugs to the Raf kinase domain (4, 5) , relief of autoinhibitory P-loop phosphorylation (6) and a more complex mechanism involving reactivation of desensitized B-Raf (7) have been proposed to explain inhibitor-induced ERK activation. Inhibitor-induced ERK activation could potentially account for the development of therapy-related tumors in the melanoma patients. These tumor harbor Ras mutations with variably increased frequency (from 17% to 60% in different studies (8) (9) (10) ). In addition, inhibitor treatment accelerates tumor development in a mouse model of chemical skin carcinogenesis (8) , which partially depends on H-Ras and involves a strong inflammatory response (11) . It is thus yet unclear whether Ras activation, in the absence of other mutations or of inflammation, is enough to license Raf inhibitor-driven tumorigenesis; and whether B-Raf or C-Raf are essential for the development of drug-induced epithelial tumors.
To test the effect of Raf inhibitors on tumor-prone epidermis, we used a transgenic mouse model in which the expression of a dominant active, farnesylated Son of Sevenless (SOS-F) in keratin 5 positive basal keratinocytes leads to the development of epidermal tumors [K5-SOS-F transgenic mice (12) ]. This system has the advantage of being cell-autonomous and not 4 dependent on inflammation, which is absolutely necessary to support the growth of chemicallyinduced skin tumors (11) . These two features allow us to focus on the effect of the inhibitors on the signaling operating in premalignant cells, reducing the impact of other cell compartments (inflammatory cells) supporting tumorigenesis. In addition, the transgenic model mimics the situation of spontaneous human cSCC, in that it induces Ras and Erk activation in the absence of somatic Ras mutations (13) , which are comparatively rare event in drug-related tumors (9) .
MATERIALS AND METHODS

Mouse Strains and inhibitor treatment.
Mouse strains and genotyping have been previously described (14) . Strains were maintained on a 129Sv/Bl6 (F1) background. Animal experiments were authorized by the Austrian Ministry of Science and Communications, following the approval by the Ethical Committee for Animal Experimentation. GDC-0879, PLX-4032, synthesized and formulated according to published procedures (WO2006/084015 and WO2007/002325), and, in selected experiments GSK1120212 (trametinib) and Y-27632 were applied daily by gavage (100mg/kg GDC-0879 in 0.5% Natrosol, citric acid pH=3.0; 100mg/kg PLX-4032, high-bioavailability formulation in 5% Klucel, HCl pH= 3.2, WO2010/114928; 0.5mg/kg GSK1120212 in DMSO/1% Natrosol; 2x15mg/kg Y-27632 in 0.5% Klucel). The Rok inhibitor Fasudil was added to the drinking water (exchanged every 3-4 days) at a concentration of 2mg/ml. Histological Analysis. Hematoxylin/eosin staining and immunohistochemistry were performed as described (14) . For BrdU incorporation, mice were injected with BrdU (12.5 mg/g body weight) 1 hr prior to tissue isolation.
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Cell Culture. Mouse keratinocytes were isolated and maintained as described (14) . HaCaT cells (15) were obtained from the DKFZ and SCC cell lines (16) were kindly provided by Gian-Paolo Dotto and maintained as previously described (16) . COS7 cells were bought from Genlantis and maintained according to the manufacturer's instruction. The cell lines were not authenticated in our lab but were used shortly after resuscitation of early passages (<5) of the original material received from the provider. 70% confluent cells were treated with inhibitors for 1 hour at 32°C or at 37°C for the COS7 cells.
Site-directed mutagenesis. Point mutation was introduced with the QuickChange site-directed mutagenesis kit (Stratagene) using pcDNA FLAG-tagged C-Raf as a template and the primers 5'-gtggctgttctgcgcaaaacacaccatgtgaacattctg-3' (forward) and 5'-cagaatgttcacatggtgtgttttgcgcagaa cagccac-3' (reverse). The mutation was verified by sequencing.
Immunoblotting and Immunoprecipitation. For ex vivo immunoblotting and
immunoprecipitation, keratinocytes were prepared as previously described (17) , but instead of plating the cells were subjected to differential centrifugation to enrich for specific epidermal layers. The K5+/K10+ layers were pooled and processed further for immunoblotting and immunoprecipitation. Cultured cells or epidermis were lysed with Laemmli buffer at 95°C for 5 min. Lysates were immunoblotted using the following primary antibodies (1:1000): ɲ-A-Raf, ɲ-BRaf and ɲ-pCofilin (Santa Cruz); ɲ-C-Raf and ɲ-SOS (BD Biosciences); ɲ-pMEK, ɲ-tMEK, ɲ-pERK and ɲ-panERK (Cell Signaling); ɲ-Cofilin, pRSK, pELK, Cyclin D1 and cFos (Abcam); ɲ-GAPDH (Millipore) and FLAG (Bethyl). Immunoprecipitation was performed as previously described (18) using ɲ-B-Raf (Santa Cruz), ɲ-C-Raf (Cell Signaling) or Rok-ɲ antibodies (BD Biosciences ) coupled 6 to ProteinG-Sepharose beads (Invitrogen). Immunoprecipitation of FLAG-tagged C-Raf was carried out using Anti-FLAG M2 affinity gel (Sigma-Aldrich).
Ras activation assay
Ras-GTP was pulled down from keratinocyte lysates using immobilized Raf-1 according to the manufacturer's recommendation (Cytoskeleton Inc).
Statistical Analysis.
Values are expressed as mean (±SD) of at least three independent experiments. p values were calculated using the two-tailed Student's t test. A p value <0.01 is considered statistically significant.
RESULTS
We have treated the K5-SOS-F transgenic mice with two selective Raf inhibitors: PLX-4032 (vemurafenib) (1) (2) (3) 19) , currently used in the clinical treatment of melanoma; and GDC-0879 (20, 21) , which is not used in the clinic but has higher affinity for Raf and reportedly increases proliferation in mouse epidermis (5) . The estimated IC 50 values of the inhibitors at 1mM ATP concentration are similar for wild type B-Raf and C-Raf; in both cases, GDC-0879 is more potent with an IC 50 of 34 nM or 180 nM against B-or C-Raf, respectively, compared with the 530 nM and 1100 nM IC 50 of the tool compound PLX-4720, the precursor of PLX-4032 (5). The inhibitors, applied daily by gavage, could be detected in mouse plasma ( Figure 1A) ; in particular, the plasma exposures to PLX-4032 were comparable to those necessary to achieve melanoma regression in patients (1, 2) . Both drugs caused a range of skin phenotypes in K5-SOS-F 7 transgenics, including the growth of preexisting tumors and the thickening of the epidermis of tail, eyelids and ears ( Figure 1B-C) . These phenotypes were already evident after 5-7 days of inhibitor treatment. The mice rapidly lost weight (around 20% in one week; Figure 1D ) and had to be euthanized. Necropsy revealed papilloma development in the squamous epithelia of oesophagus and forestomach in 13 out of 13 animals/inhibitor ( Figure 1E ), likely causing weight loss and death. These epithelia express K5, but they do not develop tumors in the absence of 
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appears to be due to a side-effect of the inhibitor in the epidermis, namely the concomitant inhibition of Rok signaling and ERK phosphorylation ( Figure S8B ), sporadically observed in other tissues (26) (27) (28) . ERK inhibition by Fasudil is not observed in the forestomach (Figure 7B ), reinforcing the concept that both ERK activation and the dimming of Rok signaling are required for the formation of Ras plus Raf inhibitor-driven epithelial tumors. Our results support a model in which inhibitor-driven Raf and ERK activation are necessary and sufficient for hyperproliferation of the epidermis; in the presence of SOS-F, differentiation is suppressed, leading to tumor formation ( Figure S9 ). This is consistent with the assumption that the level of ERK activation is rate-limiting for tumorigenesis (1), a concept which advocates the combination therapies using Raf and MEK inhibitors (30) currently being tested in clinical trials (31, 32) . In support of this, PLX-4032, a weaker promoter of Raf activation and ERK phosphorylation, does not lead to increased proliferation in wild-type epidermis ( Figure S1 C, differential centrifugation for the production of K5/K10+-enriched epidermal lysates.
DISCUSSION
Epidermal lysates were centrifuged at progressively increasing g, and the pellets were subjected to immunoblotting. The pellets of the first two centrifugation steps were enriched in K5+ basal cells and K10+ suprabasal cells. Active transglutaminase 1 (Tgase1), a marker of progressive differentiation, was present in increasing amounts in the pellets of the last three centrifugation steps. All the proteins at study were present in the first two pellets, which were therefore pooled and used to determine the effect of inhibitor treatment on signaling in vivo. D, GDC-0879 and, to a lesser extent, PLX-4032 promote Raf heterodimerization in K5-SOS-F epidermis from systemically inhibitor treated mice. The presence of A-, B-, and C-Raf, total (tMEK), phosphorylated MEK (pMEK), total (tERK) and phosphorylated ERK (pERK) was detected by immunoblotting. GAPDH is shown as a loading control. D, DMSO. *longer exposure. 
